IDEX (IEX) Q3 2026 earnings review
IDEX raises its full-year outlook as industrial sales recover
IDEX, the maker of industrial pumps, rescue tools, and scientific components, turned its order backlog into faster shipments while its lagging industrial units returned to growth. Sales and orders from businesses owned a year ago rose 8% and 13%, lifting profit per share excluding one-offs by 15% to $2.33. Chief executive Eric D. Ashleman raised the full-year outlook for a third time, which by our math points to about 9% sales growth and 9% profit growth in the fourth quarter.
| Sales from businesses owned a year ago | +8% above the 5%–7% outlook |
|---|---|
| Profit per share, excluding one-offs | $2.33 +15% from a year ago |
| Orders from businesses owned a year ago | $991M +13% from a year ago |
| Full-year profit per share outlook | Raised $0.16 middle of the range: $8.94 (+12%) |
⚖️ Verdict: 🟢 Bullish
The story got better because the industrial divisions joined the recovery and profit margins expanded without last quarter's one-time tariff refund. Both Fluid & Metering and Fire & Safety accelerated on higher volumes, easing fears that the company relies solely on artificial intelligence data centers. One caution: employee bonuses and newly acquired businesses kept Health & Science profit flow-through at 37% by our math, and order growth slowed from last quarter's 28% pace.
The question now is whether the slower 13% order growth marks a return to normal customer buying or the start of a pause in data center and chip equipment orders. Either the four-quarter backlog build keeps revenue growing near 8% into 2027, or a pullback by those large buyers exposes how much growth came from a few customers. Next quarter's order intake and 2027 outlook will settle it.
🐂 Bull Case
Health & Science Orders Turn Into Shipments
Health & Science Technologies (HST) is IDEX's largest division, making precision components for medical gear, chipmaking tools, and satellites. While rapid order growth drives the growth story, the reliance on a small group of artificial intelligence and semiconductor buyers is also the company's biggest concentration risk. This quarter, the division's order backlog turned into faster deliveries, lifting sales from businesses owned a year ago by 13%.
- Division sales: $433.5 million, up 14% reported and 13% from businesses owned a year ago
- Company-wide orders: $991.2 million, up 13% from a year ago, or 1.04 times sales by our math
- Four-quarter excess of orders over sales: $372 million by our math
The company said growth came "primarily due to AI-driven demand for data center power and semiconductor markets, as well as strength in space and defense and positive price". Because orders exceeded sales by another $39.5 million by our math, the division is still adding to its backlog even as factory shipments speed up.
What to watch: Health & Science order growth in the fourth quarter, when the division compares against last year's 34% jump. Holding orders steady against that high bar would show that data center and chip customers are still expanding capacity.
Industrial Volumes Begin to Recover
IDEX's two traditional industrial divisions — Fluid & Metering Technologies, which makes industrial pumps and water meters, and Fire & Safety/Diversified Products, which makes rescue tools, clamps, and paint dispensers — had struggled with flat or falling customer volumes for a year. Chief executive Eric D. Ashleman said "momentum is broadening across the rest of the portfolio".
The numbers back him up, because both divisions accelerated this quarter. Fire & Safety/Diversified underlying sales rose 6%, reversing four straight quarters of declines on "higher volumes in our BAND-IT and Fire & Safety businesses as well as positive price". Fluid & Metering underlying sales grew 4%, up from 1% last quarter, as municipal water, semiconductor, and general industrial demand outweighed weak chemical, agriculture, and energy markets.
What to watch: Fluid & Metering and Fire & Safety underlying sales growth in the fourth quarter. A second straight quarter of volume gains across both divisions would confirm a durable industrial recovery.
Margins Rise Without Tariff Refunds
Last quarter's profit margins benefited from a one-time government refund of invalidated tariffs, raising the question of whether margins would hold up on their own. IDEX answered that by lifting gross margin 0.6 percentage points from a year ago to 45.1%, as the cost of making products fell from 55.5% of sales to 54.9% by our math.
Selling, general, and administrative overhead also dropped by 0.4 percentage points of sales to 22.9%, helping push operating margin up 0.7 percentage points to 21.9% by our math. Ashleman credited 8020, the company's method of focusing resources on its most profitable customers and products, along with higher factory volumes.
What to watch: company-wide Ebitda margin excluding one-offs in the fourth quarter. Holding above 27.0% during a seasonally slower quarter would prove that factory efficiency gains are sticking.
🐻 Bear Case
Bonuses and Acquisitions Cap Margin Gains
Ashleman highlighted "strong incremental margins on the increased volume" and the company's efforts to integrate acquired businesses. However, the segment numbers show that higher employee bonus costs and recently bought companies are still holding back profit flow-through.
In Health & Science, Ebitda margin excluding one-offs rose 1.1 percentage points to 28.8%, which equals a 37.0% profit flow-through on new sales by our math — short of the 40% benchmark the company targets. The release noted that volume gains were "partially offset by higher employee-related costs, including variable compensation and the impact of acquisitions". In Fluid & Metering, unfavorable product mix and bonus costs held the margin gain to 0.2 percentage points, while unallocated corporate expenses jumped 17.5% to $25.5 million.
What to watch: Health & Science incremental Ebitda margin in the fourth quarter. A reading below 37% on double-digit sales growth would show that acquired businesses are still diluting the division's profitability.
Backlog and AI Revenue Remain Undisclosed
IDEX's growth case rests on orders booked for future delivery, yet the engineered-products maker never publishes its total dollar backlog or how much of it ships in 2026 versus 2027. It also omits standalone sales figures for the data center, semiconductor, and defense markets that Ashleman says are driving the company.
That missing detail matters more this quarter because order growth cooled from 28% in the second quarter to 13% in the third, with total orders stepping down from $1,071.6 million to $991.2 million. Without a backlog balance or a delivery schedule, investors cannot tell how much of the four-quarter order surge has already shipped and how much remains for next year.
What to watch: the revenue footnote in the third-quarter 10-Q filing and management's 2027 outlook in February. If the company still withholds a backlog figure, any slowdown in data center orders will show up only after quarterly bookings drop.
Risks this quarter didn't answer
Three standing concerns from prior quarters could not be checked from the earnings release alone and await the conference call or quarterly filing.
- Life sciences demand: the release did not mention life sciences or medical instrument volumes, which makes up a third of Health & Science sales and had been growing only mid-single digits.
- Health & Science plant closure: IDEX booked another $0.8 million in factory-closure costs ($0.7 million in accelerated depreciation) plus $2.2 million in division restructuring, without naming the plant or the expected savings.
- Trade and tariff costs: the release cited price-versus-cost headwinds in Fire & Safety and gross margin, but gave no update on newly re-imposed tariffs.
💲 Other KPIs
Free cash flow — operating cash left after capital spending — rose 13.6% from a year ago, improving from a 6% drop in the first quarter. The company converted 124% of its profit excluding one-offs into cash, even as it increased capital spending by 70.3% to $25.2 million to expand factory capacity.
Stockpiles of raw materials and goods rose 10.4% since December and 6.9% from a year ago by our math, absorbing $9.9 million of cash in the quarter. The industrial group is carrying more inventory to fulfill its $991.2 million quarterly order flow.
Total debt minus cash fell by $91.4 million over the first nine months of the year by our math, as the maker of pumps and valves paid down $107.6 million net on its credit line this quarter and extended the $800 million facility to 2031. It also spent $74.6 million on buybacks, cutting diluted shares by 1.6% from a year ago to 74.0 million.
🔮 Guidance
Raised. The middle of the full-year outlook moved up 1.15 percentage points to 6.65% growth. By our math, against 6.0% growth over the first nine months, the plan leaves about 8.5% underlying sales growth for the fourth quarter, up from 1.0% in last year's fourth quarter. It is the third raise this year, and smaller than the first two: +2.0 points, +2.0 points, +1.15 points.
Raised. Management lifted the middle of the full-year profit range by $0.16 to $8.935 per share, or about 12% growth. By our math, subtracting $6.65 earned in the first nine months leaves $2.26 to $2.31 for the fourth quarter (+8.8% from a year ago at the middle, down from 14.8% in the third quarter). Third raise this year (+$0.20, +$0.325, +$0.16); if its 7.7% average quarterly beat holds, fourth-quarter profit would reach $2.46.
❓ Key Questions
Why does the fourth-quarter outlook imply slower profit growth?
By our math, the full-year plan points to 8.5% underlying sales growth in the fourth quarter, but only 8.8% growth in profit per share excluding one-offs ($2.26 to $2.31), down from 15% in the third quarter. Management did not issue a standalone fourth-quarter outlook table in the release.
How big is the dollar backlog for 2027?
Orders have exceeded sales by $372 million over the past four quarters by our math, but order growth slowed from 28% in the second quarter to 13% in the third. Without a dollar backlog figure, investors cannot size the 2027 revenue cushion.
What happened to life sciences volumes in the third quarter?
Life sciences makes up a third of Health & Science sales and had been lagging because of slow research funding and an optical-systems product transition. The release did not mention life sciences performance at all.
Which Health & Science plant is closing, and at what savings?
IDEX booked another $0.8 million of restructuring charges in gross margin for an anticipated facility closure in Health & Science ($1.3 million year-to-date), plus $2.2 million in segment restructuring. It still has not named the site, total cost, or annual savings.